{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:50:30Z","timestamp":1790272230194,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017804","name":"City of Hope","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Multiple myeloma is a chronic malignancy and with evolving treatment options, understanding the economic burden and cost-effectiveness of therapies is crucial for clinicians and researchers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>In this, we review the recent approval of Bispecific antibodies and CAR-T for myeloma and their cost implications, including direct and indirect costs. We compare this to current regimens and provide cost comparisons in this review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>We conclude that the use of more effective therapies such as CAR-T in earlier lines of therapies may be more cost-effective depending on the country and model used. Further studies are essential to better understand the cost-effectiveness of bispecific antibodies including head-to-head comparisons to CAR-T therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11899-024-00748-5","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T01:49:39Z","timestamp":1735955379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies"],"prefix":"10.1007","volume":"20","author":[{"given":"Praneeth Reddy","family":"Keesari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Samuels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charan Thej Reddy","family":"Vegivinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashwitha Sai","family":"Pulakurthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revathi","family":"Kudithi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meekoo","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Janakiram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"748_CR1","unstructured":"American Cancer Society. Key Statistics About Multiple Myeloma. American Cancer Society website. https:\/\/www.cancer.org\/cancer\/types\/multiple-myeloma\/about\/key-statis-tics.html. Published 2023. Accessed July 12, 2024."},{"issue":"9","key":"748_CR2","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1200\/JCO.2009.25.2114","volume":"28","author":"H Ludwig","year":"2010","unstructured":"Ludwig H, Bolejack V, Crowley J, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010;28(9):1599\u2013605.","journal-title":"J Clin Oncol"},{"issue":"8","key":"748_CR3","first-page":"917","volume":"29","author":"J Yang","year":"2023","unstructured":"Yang J, Boytsov N, Carlson JJ, Barthold D. Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis. J Manag Care Spec Pharm. 2023;29(8):917\u201326.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"748_CR4","first-page":"449","volume":"25","author":"S Hollmann","year":"2019","unstructured":"Hollmann S, Moldaver D, Goyert N, Grima D, Maiese EM. A u. S. Cost analysis of triplet regimens for patients with previously treated multiple myeloma. J Manag Care Spec Pharm. 2019;25(4):449\u201359.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"748_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2217\/fon-2020-1003","volume":"17","author":"D Madduri","year":"2021","unstructured":"Madduri D, Hagiwara M, Parikh K, et al. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. Future Oncol. 2021;17(5):503\u201315.","journal-title":"Future Oncol"},{"issue":"2","key":"748_CR6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40487-021-00175-z","volume":"9","author":"S Jagannath","year":"2021","unstructured":"Jagannath S, Joseph N, He J, et al. Healthcare costs incurred by patients with multiple myeloma following triple class exposure (Tce) in the us. Oncol Ther. 2021;9(2):659\u201369.","journal-title":"Oncol Ther"},{"issue":"1","key":"748_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12935-023-03045-y","volume":"23","author":"M Noori","year":"2023","unstructured":"Noori M, Yazdanpanah N, Rezaei N. Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis. Cancer Cell Int. 2023;23(1):193.","journal-title":"Cancer Cell Int"},{"issue":"5","key":"748_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","volume":"31","author":"M Sheykhhasan","year":"2024","unstructured":"Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, et al. CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther. 2024;31(5):667\u201386.","journal-title":"Cancer Gene Ther"},{"key":"748_CR9","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1200\/EDBK_200867","volume":"38","author":"SV Rajkumar","year":"2018","unstructured":"Rajkumar SV. Value and cost of myeloma therapy. Am Soc Clin Oncol Educ Book. 2018;38:662\u20136.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"748_CR10","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/jha2.798","volume":"4","author":"DB Bayani","year":"2023","unstructured":"Bayani DB, Lin YC, Ooi MG, Tso ACY, Wee HL. Real-world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore. EJHaem. 2023;4(4):1013\u20138.","journal-title":"EJHaem"},{"issue":"1","key":"748_CR11","doi-asserted-by":"publisher","first-page":"IJH05","DOI":"10.2217\/ijh-2018-0004","volume":"7","author":"J Ashcroft","year":"2018","unstructured":"Ashcroft J, Judge D, Dhanasiri S, Taylor-Stokes G, Middleton C. Chart review across EU5 in MM post-ASCT patients. Int J Hematol Oncol. 2018;7(1):IJH05.","journal-title":"Int J Hematol Oncol"},{"issue":"5","key":"748_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/13696998.2017.1421546","volume":"21","author":"S Gonzalez-McQuire","year":"2018","unstructured":"Gonzalez-McQuire S, Yong K, Leleu H, et al. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. J Med Econ. 2018;21(5):450\u201367.","journal-title":"J Med Econ"},{"issue":"1","key":"748_CR13","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1080\/13696998.2022.2133823","volume":"25","author":"M Choon-Quinones","year":"2022","unstructured":"Choon-Quinones M, Zelei T, Barnett M, et al. Beyond medicines\u2019 barriers: exploring the true cost of multiple myeloma. J Med Econ. 2022;25(1):1167\u201375.","journal-title":"J Med Econ"},{"issue":"12","key":"748_CR14","first-page":"5007","volume":"24","author":"M Touati","year":"2016","unstructured":"Touati M, Lamarsalle L, Moreau S, et al. Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home. Support Care Cancer. 2016;24(12):5007\u201314.","journal-title":"Support Care Cancer"},{"issue":"16_suppl","key":"748_CR15","doi-asserted-by":"publisher","first-page":"e18811","DOI":"10.1200\/JCO.2022.40.16_suppl.e18811","volume":"40","author":"N Gupta","year":"2022","unstructured":"Gupta N, Tai MH, Kaila S, et al. Real-world healthcare resource utilization and costs among patients with multiple myeloma in the United States. JCO. 2022;40(16_suppl):e18811\u2013e18811.","journal-title":"JCO"},{"issue":"2","key":"748_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/ejh.12876","volume":"99","author":"D Robinson","year":"2017","unstructured":"Robinson D, Orlowski RZ, Stokes M, et al. Economic burden of relapsed or refractory multiple myeloma: Results from an international trial. Eur J Haematol. 2017;99(2):119\u201332.","journal-title":"Eur J Haematol"},{"issue":"10","key":"748_CR17","first-page":"1019","volume":"24","author":"D Merola","year":"2018","unstructured":"Merola D, Yong C, Noga SJ, Shermock KM. Costs associated with productivity loss among u. S. Patients newly diagnosed with multiple myeloma receiving oral versus injectable chemotherapy. J Manag Care Spec Pharm. 2018;24(10):1019\u201326.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"748_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/ejh.13298","volume":"103","author":"G Jackson","year":"2019","unstructured":"Jackson G, Galinsky J, Alderson DEC, et al. Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy. Eur J Haematol. 2019;103(4):393\u2013401.","journal-title":"Eur J Haematol"},{"issue":"12","key":"748_CR19","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1016\/j.jval.2022.09.534","volume":"25","author":"S Miguel","year":"2022","unstructured":"Miguel S, Pedrosa H, Carrilho M, et al. Ee287 indirect costs of multiple myeloma in portugal. Value in Health. 2022;25(12):S110.","journal-title":"Value in Health"},{"key":"748_CR20","doi-asserted-by":"publisher","first-page":"569500","DOI":"10.3389\/fpubh.2020.569500","volume":"8","author":"A Carta","year":"2020","unstructured":"Carta A, Conversano C. On the use of markov models in pharmacoeconomics: pros and cons and implications for policy makers. Front Public Health. 2020;8:569500.","journal-title":"Front Public Health"},{"key":"748_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.orhc.2019.04.001","volume":"21","author":"C del Campo","year":"2019","unstructured":"del Campo C, Bai J, Keller LR. Comparing Markov and non-Markov alternatives for cost-effectiveness analysis: Insights from a cervical cancer case. Oper Res Health Care. 2019;21:32\u201343.","journal-title":"Oper Res Health Care"},{"issue":"10","key":"748_CR22","doi-asserted-by":"publisher","first-page":"7285","DOI":"10.3390\/curroncol29100574","volume":"29","author":"AM Guggenbickler","year":"2022","unstructured":"Guggenbickler AM, Barr HK, Hoch JS, Dewa CS. Rapid review of real-world cost-effectiveness analyses of cancer interventions in canada. Curr Oncol. 2022;29(10):7285\u2013304.","journal-title":"Curr Oncol"},{"issue":"4","key":"748_CR23","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.3390\/curroncol30040310","volume":"30","author":"HK Barr","year":"2023","unstructured":"Barr HK, Guggenbickler AM, Hoch JS, Dewa CS. Real-world cost-effectiveness analysis: how much uncertainty is in the results? Curr Oncol. 2023;30(4):4078\u201393.","journal-title":"Curr Oncol"},{"issue":"1","key":"748_CR24","doi-asserted-by":"publisher","first-page":"118.e1","DOI":"10.1016\/j.jtct.2023.10.001","volume":"30","author":"C Yamamoto","year":"2024","unstructured":"Yamamoto C, Minakata D, Yokoyama D, et al. Cost-effectiveness of anti-bcma chimeric antigen receptor t cell therapy in relapsed\/refractory multiple myeloma. Transplant Cell Ther. 2024;30(1):118.e1-118.e15.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"748_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1080\/13696998.2023.2207742","volume":"26","author":"W Wu","year":"2023","unstructured":"Wu W, Ding S, Mingming Z, et al. Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed\/refractory multiple myeloma in China. J Med Econ. 2023;26(1):701\u20139.","journal-title":"J Med Econ"},{"key":"748_CR26","doi-asserted-by":"publisher","first-page":"107327482211429","DOI":"10.1177\/10732748221142945","volume":"30","author":"KA Kapinos","year":"2023","unstructured":"Kapinos KA, Hu E, Trivedi J, Geethakumari PR, Kansagra A. Cost-effectiveness analysis of car t-cell therapies vs antibody drug conjugates for patients with advanced multiple myeloma. Cancer Control. 2023;30:10732748221142944.","journal-title":"Cancer Control"},{"issue":"9","key":"748_CR27","first-page":"1315","volume":"27","author":"M Beinfeld","year":"2021","unstructured":"Beinfeld M, Lee S, McQueen B, Fluetsch N, Pearson SD, Ollendorf DA. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma. J Manag Care Spec Pharm. 2021;27(9):1315\u201320.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"748_CR28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","volume":"11","author":"PJ Teoh","year":"2021","unstructured":"Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021;11(4):84.","journal-title":"Blood Cancer J"},{"issue":"9","key":"748_CR29","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29(9):2295\u2013306.","journal-title":"Nat Med"},{"issue":"1","key":"748_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-022-00434-9","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y, An L, Huang R, et al. Strategies to enhance CAR-T persistence. Biomark Res. 2022;10(1):86.","journal-title":"Biomark Res"},{"key":"748_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","volume":"25","author":"LA KankeuFonkoua","year":"2022","unstructured":"KankeuFonkoua LA, Sirpilla O, Sakemura R, Siegler EL, Kenderian SS. CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. Mol Ther Oncolytics. 2022;25:69\u201377.","journal-title":"Mol Ther Oncolytics"},{"issue":"11","key":"748_CR32","doi-asserted-by":"publisher","first-page":"e005091","DOI":"10.1136\/jitc-2022-005091","volume":"10","author":"N Camviel","year":"2022","unstructured":"Camviel N, Wolf B, Croce G, Gfeller D, Zoete V, Arber C. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization. J Immunother Cancer. 2022;10(11):e005091.","journal-title":"J Immunother Cancer"},{"issue":"Suppl 2","key":"748_CR33","first-page":"S13","volume":"98","author":"G Ravi","year":"2023","unstructured":"Ravi G, Costa LJ. Bispecific T-cell engagers for treatment of multiple myeloma. Am J Hematol. 2023;98(Suppl 2):S13\u201321.","journal-title":"Am J Hematol"},{"key":"748_CR34","doi-asserted-by":"publisher","first-page":"1348955","DOI":"10.3389\/fimmu.2024.1348955","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Zhao A, Zhu J, Niu T. Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials. Front Immunol. 2024;15:1348955.","journal-title":"Front Immunol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-024-00748-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-024-00748-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-024-00748-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:20:14Z","timestamp":1769044814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-024-00748-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["748"],"URL":"https:\/\/doi.org\/10.1007\/s11899-024-00748-5","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"16 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"3"}}